Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nope, not when 33 million also sell. Look at May 10th's debacle. We need multiple 100M share days, back to back, with tons of press coverage. Otherwise, $1.
TLD is not something a Journal prevents a company from PR'ing. So, what is the reason they won't do it? The only logical answer is that they do not have a Journal acceptance. if they were accepted, and in review, then the usual embargo protocols would be in play and the company would likely choose a date close to expected publication. Since they are "pursuing" a Journal, more cryptic BS, they don't have an exact embargo policy to follow.
So, Oct 5th, 2020 to may 10th, 2022:
"Please refer back to plan we stated in the Oct 5th PR."
May 11th, 2022 ---???
Self-imposed journal embargo and no ASM. AND, we have no idea if a Journal has even accepted the manuscript. "pursuing"
You just can't make this up. The ridiculous notion that things would be worse if they just told the truth and let us know where things stand is my issue. Definition of insanity at work.
LOL, seriously? You need worldwide sales distribution after you spend $50 million getting approvals....it's suicide to go it alone, IMO.
The stock price will move in advance of any article, believe me. Someone will know. So, at this point, don't expect and article anytime soon.
No ASM.
No Journal
No PR's (so, no "official" topline)
This high-wire act is getting dangerous, IMO. They clearly are dancing around formal announcement of TLD. Is that because of the financing rounds they recently did? Some of those covenants revolved around TLD and private placement following TLD. The second loan starts repayment any day now as well. So, that will be two large loans that need monthly payments. Are they now forced to do another? At even worse terms? Do they not want to hold an ASM because of what may have already happened behind the scenes? We are now 48 days (at the latest) from next 10Q. Will that be the next time we hear from the company? Will we see ANY UK specials revenue?
There are so many questions they COULD answer and choose not to. They do not care about the current share price, which is a fiduciary question, IMO. But worse, all the loyal shareholders for the past two years have not gotten what was promised. Appears they could care less.
LOL, still using covid.
Define "matter of time"?
I thought it would be a matter of time when I bought almost 8 years ago and thought I would be able to sell at some point after a completed phase 3 trial and TLD release. Still waiting.
Low volume take down. Groundhog day.
Unless we never get a publication. Then what, we don't wake up?
Remember, DI recently said publication was a "goal"....which says to me, not a requirement. So, original two year quiet period plan of TLD and Journal as close together as possible may or may not be the current plan. But, how would we know. They are now in a self-imposed embargo while "seeking" a Journal for the manuscript. Can't make this up.
Aaaah, yes...it is all starting to make sense now.
Please add your question (to AOO) for context. Thanks.
Yes. What I believe most are not lending credibility to is the fact that LP could F this all up to zero. Depending how she plays this, it could be worth 20B or 0. That's why the silence is concerning to me. The science is there. The data are there. BUT...maybe she has alienated BP and their advances for buyout. Maybe this path through the UK won't force the FDA to eventually approve it. Why is a Journal article a "goal" now instead of the TLD/Journal package they said was the plan back in 2020. Why are they doing all these repeat presentations without PR's and getting the word out? It is a slippery slope that could cost patients and shareholders everything.
There are several larger entities who DO have the manufacturing capability. LP should be wrapping a bow around this and selling it to BP, ASAP...for the good of patients and shareholders.
??? So, LP said they do not have manufacturing capability for approval in US? Followed by a projection that this will not grow very quickly because it is a personalized therapy?
Who would that be?
It's a joke, there hasn't been a two year, self-imposed quiet period in the history of publicly traded markets. Deflection to a Journal embargo is priceless too. What's the longest "journal embargo" ever? Start your timers....already at least 6 weeks and counting.
Serious investors demand accountability from the mgmt of the companies they invest in.
Nothingburger. First few guppies bought over .70 and here we go back under .70....this goes nowhere until the company takes an aggressive stance and starts defending and broadcasting the results.
Ok, I get it, they were all there. BUT WHY?
1. Were they going to visit and tour the Advent facility afterwards?
2. Are they meeting with MHRA officials or NICE about approvals?
3. Could they just be going for UK approval first as the company has alluded to before as a possible path?
Why are they there and why are they still silent?
And, just like that, back to red.
10:30 am is the usual PR time for NWBO, so you have to wait 7 more minutes to be correct.
All true. I just wish there were more supports who were more vocal about the potential here, including the company.
Not even sure we can get through .70 this morning.
Unfortunately no PR again or anything from the company.
Sounds like the cross-over comparison to ECA will hopefully suppress concerns for strict inclusion criteria, but that question was clearly a negative bias.
Most questions, other than the last were more skeptical and critical, IMO. No "WOW, this is a game-changer." The last question, a Dr. stated that people are asking for this treatment every week in her clinic....
I'd like to be surprised as well.
Abstract was submitted. Received "Top Scoring Oral" Abstract. But only 20 minutes. So, would be great if they presented additional data and results. Who knows.
Journal is either imminent or a problem, IMO. It seems that the multiple conferences and appearances were planned to be part of the victory tour. However, no formal PR of TLD from company says something is off, at least in timeline. ASM, IMO, will not happen without formal TLD (and hopefully Journal). I do not believe they can ask for what they want to ask for without them.
I've been asking that question since May 10th. EMBARGO is the word of the month. BTW, that's the new word for quiet period. Like orange is the new black kind of thing.
Not sure. ALL authors, maybe just Ashkan presenting? It's only 20 minutes.
Nope EST. Just laughing. These could be the types of back and forth conversations happening in the NWBO board room, but I pray to God that is not the case.
LOL. It's Thursday morning for BOTH! One is 5 hours ahead of the other.....meaning UK sees 10AM five hours before us.
What's the soup de jour? That's the soup of the day....hmmm, that sounds good, I'll have that.
Who's on first?
Presentations are Thursday, not tomorrow.
Probably not much new. Although I am more curious to hear of Stupp says anything about the Phase 3 DCVAX as a lead in to the presentation. Ashkan has also likely treated more people directly with DCVax than any other Dr....possibly even LL.
TOP SCORING ORAL ABSTRACT!
We get better promotion from conferences!
So, in the Abstracts list for BNOS 2022, it shows ALL our top guns contributed.
Schedule is for Thursday morning presentations:
09.45 Tips on organising a successful clinical trial Roger Stupp
10.10 Autologous tumor lysate-loaded dendritic cell vaccination in patients with newly diagnosed
and recurrent glioblastoma - Survival results from a phase 3 trial
Keyoumars Ashkan
BRITISH NEURO-ONCOLOGY SOCIETY ANNUAL MEETING 2022
Table of Contents
Top Scoring Oral (20 mins)
Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination in Patients with Newly Diagnosed and Recurrent Glioblastoma: Survival Results from a Phase 3 Trial
Mr. Keyoumars Ashkan, Prof. Dr. Linda M. Liau, Dr. Marnix L. Bosch
No, this is new. Last 18 months it was "we are working hard to get this across the finish line"....meaning TLD and Journal. Neither of which the company has done (directly).